Morgan Stanley Reiterates Overweight, Raises PT On Boston Scientific On Path To 2017

In a report published Wednesday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating on

, and raised the price target from $17.00 to $20.00. In the report, Morgan Stanley noted, "Strong YTD performance should not distract from Boston's long term restructuring story, which still has years to go. We expect the May analyst day to shed light on durable growth and margins that can extend beyond the 25% 2017 target. We remain Overweight and raise our price target to $20." Boston Scientific closed on Tuesday at $17.40.